Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

Abstract

Early-phase trials with monoclonal antibodies targeting PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death 1 ligand 1) have demonstrated durable clinical responses in patients with non-small-cell lung cancer (NSCLC). However, current assays for the prognostic and/or predictive role of tumor PD-L1 expression are not standardized with respect to either quantity or distribution of expression.

Journal

Journal ID (iso-abbrev): JAMA Oncol

Title: JAMA oncology

ISSN (Electronic): 2374-2445

ISSN (Print): 2374-2437

Publication date (Electronic): Jan 2016

Volume: 2

Issue: 1

Affiliations

[1 ] Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut2Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.

[2 ] Department of Biostatistics, Yale University School of Public Health, New Haven, Connecticut.

[3 ] Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.

[4 ] Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio.

[5 ] Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut.

Article

Publisher Item ID: 2469338 Mid ID: NIHMS780059

DOI: 10.1001/jamaoncol.2015.3638

PubMed ID: 26562159